Yahoo Finance

Prolium Bioscience Announces First Patient Dosed in its Multinational, Phase 1/2 Study of PRO-203 in Systemic Sclerosis, and Last Patient, Last Visit in an Investigator-Led ...

NEW YORK, June 22, 2026 (GLOBE NEWSWIRE) -- Prolium Bioscience, Inc. (Prolium), a clinical stage biotechnology company, today announced that the first patient has been dosed in a multinational, ...
Yahoo Finance

Prolium Bioscience Launches with $50 Million and Announces First Patients Dosed with PRO-203, a Potential Best-in-Class CD20xCD3 T-Cell Engager, for Severe Autoimmune Disease

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Prolium Bioscience, Inc. (Prolium), a clinical stage biotechnology company, today announced its launch with a $50 million Series A Financing to develop PRO ...